An evaluation of Ibrutinib for the treatment of Waldenstrom macroglobulinaemia
Sign Up to like & getrecommendations! Published in 2020 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2020.1770727
Abstract: ABSTRACT Introduction Waldenstrom Macroglobulinaemia (WM) is a heterogenous condition which poses a challenge to manage. Novel therapies such as Ibrutinib have been shown to be efficacious in treating WM. The landscape of Ibrutinib’s role in… read more here.
Keywords: ibrutinib; ibrutinib treatment; waldenstrom macroglobulinaemia; evaluation ibrutinib ... See more keywords
Ibrutinib Treatment in Early Stage CLL Prolongs Time to Active Disease.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2021-166
Abstract: Ibrutinib treatment extended time to active disease in early stage chronic lymphocytic leukemia. read more here.
Keywords: ibrutinib treatment; active disease; early stage; time active ... See more keywords
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021006434
Abstract: Key Points Long-term RESONATE-2 data show sustained PFS and OS benefits (medians not reached) for first-line ibrutinib treatment in patients with CLL. Forty-two percent of patients continued ibrutinib for up to 8 years; dose management… read more here.
Keywords: ibrutinib; treatment patients; first line; line ibrutinib ... See more keywords
Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15020507
Abstract: Simple Summary Ibrutinib is an established standard of care in the first-line treatment of chronic lymphocytic leukemia. Since ibrutinib is given continuously, data on long-term treatment, outcomes, and safety are essential to inform clinical decision… read more here.
Keywords: treatment years; chronic lymphocytic; resonate study; ibrutinib treatment ... See more keywords